The Ron receptor tyrosine kinase activates c-Abl to promote cell proliferation through tyrosine phosphorylation of PCNA in breast cancer

Oncogene

Volumn 33, Issue 11, 2014, Pages 1429-1437

  Zhao, H ^a   Chen, M S ^a   Lo, Y H ^a   Waltz, S E ^a,b   Wang, J ^c   Ho, P C ^a   Vasiliauskas, J ^a   Plattner, R ^d   Wang, Y L ^a   Wang, S C ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^d UNIVERSITY OF KENTUCKY   (United States)

Author keywords

c Abl; PCNA; receptor tyrosine kinase; Ron; tyrosine phosphorylation; Y211

Indexed keywords

ABELSON KINASE; CYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; HEPATOCYTE GROWTH FACTOR LIKE PROTEIN; IMATINIB; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN TYROSINE KINASE; RON RECEPTOR TYROSINE KINASE; SCATTER FACTOR; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN ANTIBODY COMPLEX; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CELL STRAIN MCF 7; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; EMBRYO; ENZYME ACTIVITY; FIBROBLAST; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IN VITRO STUDY; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TUMOR GROWTH;

BREAST NEOPLASMS; CELL PROLIFERATION; FEMALE; HUMANS; PHOSPHORYLATION; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTO-ONCOGENE PROTEINS C-ABL; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84896399420     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.84     Document Type: Article

References (72)

1. Moldovan GL, Pfander B, Jentsch S. PCNA, the maestro of the replication fork. Cell 2007; 129: 665-679. (Pubitemid 46802385)
2. Ayyagari R, Impellizzeri KJ, Yoder BL, Gary SL, Burgers PM. A mutational analysis of the yeast proliferating cell nuclear antigen indicates distinct roles in DNA replication and DNA repair. Mol Cell Biol 1995; 15: 4420-4429.
3. Lehmann AR. Translesion synthesis in mammalian cells. Exp Cell Res 2006; 312: 2673-2676. (Pubitemid 44162919)
4. Essers J, Theil AF, Baldeyron C, van Cappellen WA, Houtsmuller AB, Kanaar R et al. Nuclear dynamics of PCNA in DNA replication and repair. Mol Cell Biol 2005; 25: 9350-9359. (Pubitemid 41507836)
5. Ulrich HD. How to activate a damage-tolerant polymerase: consequences of PCNA modifications by ubiquitin and SUMO. Cell Cycle 2004; 3: 15-18. (Pubitemid 40268577)
6. Maga G, Hubscher U. Proliferating cell nuclear antigen (PCNA): a dancer with many partners. J Cell Sci 2003; 116: 3051-3060. (Pubitemid 37038954)
7. Matunis MJ. On the road to repair: PCNA encounters SUMO and ubiquitin modifications. Mol Cell 2002; 10: 441-442. (Pubitemid 35284165)
8. Marti TM, Kunz C, Fleck O. DNA mismatch repair and mutation avoidance pathways. J Cell Physiol 2002; 191: 28-41. (Pubitemid 34195215)
9. Paunesku T, Mittal S, Protic M, Oryhon J, Korolev SV, Joachimiak A et al. Proliferating cell nuclear antigen (PCNA): ringmaster of the genome. Int J Radiat Biol 2001; 77: 1007-1021. (Pubitemid 32977930)
10. Kelman Z. PCNA: structure, functions and interactions. Oncogene 1997; 14: 629-640. (Pubitemid 27095854)
11. Komatsu K, Wharton W, Hang H, Wu C, Singh S, Lieberman HB et al. PCNA interacts with hHus1/hRad9 in response to DNA damage and replication inhibition. Oncogene 2000; 19: 5291-5297.
12. Wang S-C, Nakajima Y, Yu Y-L, Xia W, Chen C-T, Yang C-C et al. Tyrosine phosphorylation controls PCNA function through protein stability. Nat Cell Biol 2006; 8: 1359-1368. (Pubitemid 44835110)
13. Zhao H, Ho P-C, Lo Y-H, Espejo A, Bedford MT, Hung M-C et al. Interaction of proliferation cell nuclear antigen (PCNA) with c-Abl in cell proliferation and response to DNA damages in breast cancer. PLoS One 2012; 7: e29416.
14. Taagepera S, McDonald D, Loeb JE, Whitaker LL, McElroy AK, Wang JY et al. Nuclear-cytoplasmic shuttling of c-ABL tyrosine kinase. Proc Natl Acad Sci USA 1998; 95: 7457-7462. (Pubitemid 28293274)
15. Baker MA, Hetherington L, Curry B, Aitken RJ. Phosphorylation and consequent stimulation of the tyrosine kinase c-Abl by PKA in mouse spermatozoa; its implications during capacitation. Dev Biol 2009; 333: 57-66.
16. Barila D, Mangano R, Gonfloni S, Kretzschmar J, Moro M, Bohmann D et al. A nuclear tyrosine phosphorylation circuit: c-Jun as an activator and substrate of c-Abl and JNK. EMBO J 2000; 19: 273-281. (Pubitemid 30042709)
17. Baskaran R, Escobar SR, Wang JYJ. Nuclear c-Abl Is a COOH-terminal repeated domain (CTD)-tyrosine kinase-specific for the mammalian RNA polymerase II: possible role in transcription elongation. Cell Growth Differ 1999; 10: 387-396. (Pubitemid 29284180)
18. Stuart JR, Gonzalez FH, Kawai H, Yuan Z-M. c-Abl interacts with the WAVE2 signaling complex to induce membrane ruffling and cell spreading. J Biol Chem 2006; 281: 31290-31297. (Pubitemid 46041393)
19. Woodring PJ, Hunter T, Wang JYJ. Regulation of F-actin-dependent processes by the Abl family of tyrosine kinases. J Cell Sci 2003; 116: 2613-2626. (Pubitemid 36857215)
20. Baskaran R, Wood LD, Whitaker LL, Canman CE, Morgan SE, Xu Y et al. Ataxia telangiectasia mutant protein activates c-Abl tyrosine kinase in response to ionizing radiation. Nature 1997; 387: 516-519. (Pubitemid 27235471)
21. Gong J, Costanzo A, Yang H-Q, Melino G, Kaelin WG, Levrero M et al. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 1999; 399: 806-809. (Pubitemid 29293179)
22. Kharbanda S, Yuan ZM, Weichselbaum R, Kufe D. Determination of cell fate by c-Abl activation in the response to DNA damage. Oncogene 1998; 17: 3309-3318. (Pubitemid 29043983)
23. Kim WJ, Rajasekaran B, Brown KD. MLH1-and ATM-dependent MAPK signaling is activated through c-Abl in response to the alkylator N-methyl-N'-nitro-N'- nitrosoguanidine. J Biol Chem 2007; 282: 32021-32031. (Pubitemid 350106463)
24. Leong CO, Vidnovic N, DeYoung MP, Sgroi D, Ellisen LW. The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers. J Clin Invest 2007; 117: 1370-1380. (Pubitemid 46718425)
25. Levav-Cohen Y, Goldberg Z, Zuckerman V, Grossman T, Haupt S, Haupt Y. c-Abl as a modulator of p53. Biochem Biophy Res Comm 2005; 331: 737-749. (Pubitemid 40615505)
26. Mantovani F, Piazza S, Gostissa M, Strano S, Zacchi P, Mantovani R et al. Pin1 links the activities of c-Abl and p300 in regulating p73 function. Mol Cell 2004; 14: 625-636. (Pubitemid 38739084)
27. Nehme A, Baskaran R, Aebi S, Fink D, Nebel S, Cenni B et al. Differential induction of c-Jun NH2-terminal kinase and c-Abl kinase in DNA mismatch repair-proficient and-deficient cells exposed to cisplatin. Cancer Res 1997; 57: 3253-3257. (Pubitemid 27351743)
28. Shafman T, Khanna KK, Kedar P, Spring K, Kozlov S, Yen T et al. Interaction between ATM protein and c-Abl in response to DNA damage. Nature 1997; 387: 520-523. (Pubitemid 27235472)
29. Shaul Y, Ben-Yehoyada M. Role of c-Abl in the DNA damage stress response. Cell Res 2005; 15: 33-35. (Pubitemid 41653962)
30. Truong T, Sun G, Doorly M, Wang JYJ, Schwartz MA. Modulation of DNA damage-induced apoptosis by cell adhesion is independently mediated by p53 and c-Abl. Proc Natl Acad ScUSA 2003; 100: 10281-10286. (Pubitemid 37071869)
31. Tsai KKC, Yuan Z-M. c-Abl stabilizes p73 by a phosphorylation-augmented Interaction. Cancer Res 2003; 63: 3418-3424. (Pubitemid 36735903)
32. Yi W, Lee T-H, Tompkins JD, Zhu F, Wu X, Her C. Physical and functional Interaction between hMSH5 and c-Abl. Cancer Res 2006; 66: 151-158. (Pubitemid 43166020)
33. Yoshida K, Yamaguchi T, Natsume T, Kufe D, Miki Y. JNK phosphorylation of 14-3-3 proteins regulates nuclear targeting of c-Abl in the apoptotic response to DNA damage. Nat Cell Biol 2005; 7: 278-285. (Pubitemid 40331129)
34. Yuan Z-M, Huang Y, Ishiko T, Kharbanda S, Weichselbaum R, Kufe D. Regulation of DNA damage-induced apoptosis by the c-Abl tyrosine kinase. Proc Natl Acad Sci USA 1997; 94: 1437-1440. (Pubitemid 27087869)
35. Yuan Z-M, Huang Y, Whang Y, Sawyers C, Weichselbaum R, Kharbanda S et al. Role for c-Abl tyrosine kinase in growth arrest response to DNA damage. Nature 1996; 382: 272-274. (Pubitemid 26251365)
36. Yuan Z-M, Shioya H, Ishiko T, Sun X, Gu J, Huang Y et al. p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage. Nature 1999; 399: 814-817. (Pubitemid 29293181)
37. Wang JY, Ki SW. Choosing between growth arrest and apoptosis through the retinoblastoma tumour suppressor protein, Abl and p73. Biochem Soc Trans 2001; 29: 666-673. (Pubitemid 33131757)
38. Agami R, Blandino G, Oren M, Shaul Y. Interaction of c-Abl and p73alpha and their collaboration to induce apoptosis. Nature 1999; 399: 809-813.
39. Yogalingam G, Pendergast AM. Abl kinases regulate autophagy by promoting the trafficking and function of lysosomal components. J Biol Chem 2008; 283: 35941-35953.
40. Srinivasan D, Plattner R. Activation of Abl tyrosine kinases promotes invasion of aggressive breast cancer cells. Cancer Res 2006; 66: 5648-5655. (Pubitemid 43927117)
41. Srinivasan D, Sims JT, Plattner R. Aggressive breast cancer cells are dependent on activated Abl kinases for proliferation, anchorage-independent growth and survival. Oncogene 2008; 27: 1095-1105. (Pubitemid 351253178)
42. Sirvent A, Boureux A, Simon V, Leroy C, Roche S. The tyrosine kinase Abl is required for Src-transforming activity in mouse fibroblasts and human breast cancer cells. Oncogene 2007; 26: 7313-7323. (Pubitemid 350115977)
43. Zhao H, Lo Y-H, Yu L, Wang S-C. Overcoming resistance to fulvestrant (ICI182, 780) by downregulating the c-ABL proto-oncogene in breast cancer. Mol Carcinog 2011; 50: 383-389.
44. Zhao H, Ou-Yang F, Chen IF, Hou MF, Yuan SS, Chang HL et al. Enhanced resistance to tamoxifen by the c-ABL proto-oncogene in breast cancer. Neoplasia 2010; 12: 214-223.
45. Lin J, Arlinghaus R. Activated c-Abl tyrosine kinase in malignant solid tumors. Oncogene 2008; 27: 4385-4391.
46. Lin J, Sun T, Ji L, Deng W, Roth J, Minna J et al. Oncogenic activation of c-Abl in non-small cell lung cancer cells lacking FUS1 expression: inhibition of c-Abl by the tumor suppressor gene product Fus1. Oncogene 2007; 26: 6989-6996. (Pubitemid 350014606)
47. Srinivasan D, Kaetzel DM, Plattner R. Reciprocal regulation of Abl and receptor tyrosine kinases. Cell Signal 2009; 21: 1143-1150.
48. Tanos B, Pendergast AM. Abl tyrosine kinase regulates endocytosis of the epidermal growth factor receptor. J Biol Chem 2006; 281: 32714-32723. (Pubitemid 46036827)
49. Wagh PK, Peace BE, Waltz SE. Met-related receptor tyrosine kinase Ron in tumor growth and metastasis. In: George F Vande Woude, George Klein (eds). Advances in Cancer Research. Academic Press: New York, 2008, pp 1-33.
50. Iwama A, Yamaguchi N, Suda T. STK/RON receptor tyrosine kinase mediates both apoptotic and growth signals via the multifunctional docking site conserved among the HGF receptor family. EMBO J 1996; 15: 5866-5875. (Pubitemid 26375508)
51. Follenzi A, Bakovic S, Gual P, Stella MC, Longati P, Comoglio PM. Cross-talk between the proto-oncogenes Met and Ron. Oncogene 2000; 19: 3041-3049. (Pubitemid 30438460)
52. Peace BE, Hughes MJ, Degen SJ, Waltz SE. Point mutations and overexpression of Ron induce transformation, tumor formation, and metastasis. Oncogene 2001; 20: 6142-6151. (Pubitemid 32964426)
53. Zinser GM, Leonis MA, Toney K, Pathrose P, Thobe M, Kader SA et al. Mammary-specific Ron receptor overexpression induces highly metastatic mammary tumors associated with b-catenin activation. Cancer Res 2006; 66: 11967-11974. (Pubitemid 46094210)
54. Peace BE, Toney-Earley K, Collins MH, Waltz SE. Ron receptor signaling augments mammary tumor formation and metastasis in a murine model of breast cancer. Cancer Res 2005; 65: 1285-1293. (Pubitemid 40270155)
55. Welm AL, Sneddon JB, Taylor C, Nuyten DSA, van de Vijver MJ, Hasegawa BH et al. The macrophage-stimulating protein pathway promotes metastasis in a mouse model for breast cancer and predicts poor prognosis in humans. Proc Natl Acad Sci USA 2007; 104: 7570-7575. (Pubitemid 47185947)
56. Leonis MA, Thobe MN, Waltz SE. Ron-receptor tyrosine kinase in tumorigenesis and metastasis. Future Oncol 2007; 3: 441-448. (Pubitemid 47250161)
57. Lee W-Y, Chen HHW, Chow N-H, Su W-C, Lin P-W, Guo H-R. Prognostic significance of co-expression of RON and MET receptors in node-negative breast cancer patients. Clin Cancer Res 2005; 11: 2222-2228. (Pubitemid 40490180)
58. Maggiora P, Marchio S, Stella MC, Giai M, Belfiore A, De Bortoli M et al. Overexpression of the RON gene in human breast carcinoma. Oncogene 1998; 16: 2927-2933. (Pubitemid 28383277)
59. O'Toole JM, Rabenau KE, Burns K, Lu D, Mangalampalli V, Balderes P et al. Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member. Cancer Res 2006; 66: 9162-9170. (Pubitemid 44521136)
60. Andoniou CE, Thien CB, Langdon WY. The two major sites of cbl tyrosine phosphorylation in abl-transformed cells select the crkL SH2 domain. Oncogene 1996; 12: 1981-1989. (Pubitemid 26154670)
61. Koleske AJ, Gifford AM, Scott ML, Nee M, Bronson RT, Miczek KA et al. Essential roles for the Abl and Arg tyrosine kinases in neurulation. Neuron 1998; 21: 1259-1272. (Pubitemid 29022529)
62. Plattner R, Irvin BJ, Guo S, Blackburn K, Kazlauskas A, Abraham RT et al. A new link between the c-Abl tyrosine kinase and phosphoinositide signalling through PLC-gamma1. Nat Cell Biol 2003; 5: 309-319. (Pubitemid 36432295)
63. McClaine RJ, Marshall AM, Wagh PK, Waltz S. Ron receptor tyrosine kinase activation confers resistance to tamoxifen in breast cacner cell lines. Neoplasia 2010; 12: 650-658.
64. Zhao H, Lo Y-H, Ma L, Waltz SE, Gray JK, Hung M-C et al. Targeting tyrosine phosphorylation of PCNA inhibits prostate cancer growth. Mol Cancer Ther 2011; 10: 29-36.
65. Thobe MN, Gurusamy D, Pathrose P, Waltz SE. The Ron receptor tyrosine kinase positively regulates angiogenic chemokine production in prostate cancer cells. Oncogene 2010; 29: 214-226.
66. Duyster J, Baskaran R, Wang JY. Src homology 2 domain as a specificity determinant in the c-Abl-mediated tyrosine phosphorylation of the RNA polymerase II carboxyl-terminal repeated domain. Proc Natl Acad Sci USA 1995; 92: 1555-1559.
67. Jones RB, Gordus A, Krall JA, MacBeath G. A quantitative protein interaction network for the ErbB receptors using protein microarrays. Nature 2006; 439: 168-174. (Pubitemid 43083134)
68. Plattner R, Kadlec L, DeMali KA, Kazlauskas A, Pendergast AM. c-Abl is activated by growth factors and Src family kinases and has a role in the cellular response to PDGF. Genes Dev 1999; 13: 2400-2411. (Pubitemid 29453611)
69. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003; 21: 2787-2799. (Pubitemid 46606324)
70. Lo YH, Ho PC, Zhao H, Wang SC. Inhibition of c-ABL sensitizes breast cancer cells to the dual ErbB receptor tyrosine kinase inhibitor lapatinib (GW572016). Antic-ancer Res 2011; 31: 789-795.
71. Furukawa T, Kubota T, Suto A, Takahara T, Yamaguchi H, Takeuchi T et al. Clinical usefulness of chemosensitivity testing using the MTT assay. J Surg Oncol 1991; 48: 188-193.
72. Plattner R, Koleske AJ, Kazlauskas A, Pendergast AM. Bidirectional signaling links the Abelson kinases to the platelet-derived growth factor receptor. Mol Cell Biol 2004; 24: 2573-2583. (Pubitemid 38326010)